Molecule Information

General Information of the Molecule (ID: Mol04059)

Name	Choline-phosphate cytidylyltransferase A (CCTalpha) ,Homo sapiens
Synonyms	CCT-alpha; CTP:phosphocholine cytidylyltransferase A; Phosphorylcholine transferase A Click to Show/Hide
Molecule Type	Protein
Gene Name	PCYT1A
Gene ID	5130
Location	chr3:196214222-196287957[-]
Sequence	MDAQCSAKVNARKRRKEAPGPNGATEEDGVPSKVQRCAVGLRQPAPFSDEIEVDFSKPYV RVTMEEASRGTPCERPVRVYADGIFDLFHSGHARALMQAKNLFPNTYLIVGVCSDELTHN FKGFTVMNENERYDAVQHCRYVDEVVRNAPWTLTPEFLAEHRIDFVAHDDIPYSSAGSDD VYKHIKEAGMFAPTQRTEGISTSDIITRIVRDYDVYARRNLQRGYTAKELNVSFINEKKY HLQERVDKVKKKVKDVEEKSKEFVQKVEEKSIDLIQKWEEKSREFIGSFLEMFGPEGALK HMLKEGKGRMLQAISPKQSPSSSPTRERSPSPSFRWPFSGKTSPPCSPANLSRHKAAAYD ISEDEED Click to Show/Hide
Function	Catalyzes the key rate-limiting step in the CDP-choline pathway for phosphatidylcholine biosynthesis. . Click to Show/Hide
Uniprot ID	PCY1A_HUMAN
Ensembl ID	ENSG00000161217
HGNC ID	HGNC:8754
*Click to Show/Hide the Complete Species Lineage*
Kingdom: Metazoa Phylum: Chordata Class: Mammalia Order: Primates Family: Hominidae Genus: Homo Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

MRAP: Metabolic Reprogramming via Altered Pathways

Drug Resistance Data Categorized by Drug

Approved Drug(s)

1 drug(s) in total

Click to Show/Hide the Full List of Drugs

Hydroxyflutamide

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Metabolic Reprogramming via Altered Pathways (MRAP)			Click to Show/Hide
Disease Class: Prostate cancer [ICD-11: 2C82.0]				[1]
Metabolic Type	Lipid metabolism
Resistant Disease	Prostate cancer [ICD-11: 2C82.0]			Disease Info
Resistant Drug	Hydroxyflutamide			Drug Info
Molecule Alteration	Expression		Down-regulation
Experimental Note	Revealed Based on the Cell Line Data
Cell Pathway Regulation	Biosynthesis of secondary metabolites		Activation	hsa01110
In Vitro Model	LNCaP cells	Prostate	Homo sapiens (Human)	CVCL_0395
	PC-3 cells	Bone	Homo sapiens (Human)	CVCL_0035
Experiment for Molecule Alteration	qRT-PCR; Western blot analysis
Experiment for Drug Resistance	Cell viability assay
Mechanism Description	Our study shows that the long-term treatment of androgen-sensitive prostate cancer cells with the antiandrogen 2-hydroxy-flutamide leads to the development of a quiescent state with stem cell-like characteristics, enabling survival in a low metabolic state and conferring drug resistance. In this context, there is a reduction in the de novo biosynthesis of phosphatidylcholine and the activation of epigenetic reprogramming.

References

Ref 1	Resistance to 2-Hydroxy-Flutamide in Prostate Cancer Cells Is Associated with the Downregulation of Phosphatidylcholine Biosynthesis and Epigenetic Modifications. Int J Mol Sci. 2023 Oct 26;24(21):15626.